Thromboxane Biosynthesis and Platelet Function in Type I Diabetes Mellitus
- 28 July 1988
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 319 (4) , 208-212
- https://doi.org/10.1056/nejm198807283190404
Abstract
It has been speculated that platelet activation may contribute to the evolution of vascular complications in patients with Type I diabetes mellitus. To address this hypothesis, we measured the plasma and urinary metabolites of thromboxane, presumably of platelet origin, and of prostacyclin, derived from endothelial cells, in addition to more conventional indexes of platelet function.This publication has 46 references indexed in Scilit:
- Aspirin in Cardiovascular DiseaseDrugs, 1988
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988
- Platelet-Inhibitor Treatment of Diabetic Nephropathy: A 10-Year Prospective StudyMayo Clinic Proceedings, 1988
- Hyperreactive Platelets and Complications of Coronary Artery DiseaseNew England Journal of Medicine, 1987
- Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urineBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1987
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986
- In Vivo Indexes of Platelet and Vascular Function during Fish-Oil Administration in Patients with AtherosclerosisNew England Journal of Medicine, 1986
- Platelets and Diabetes MellitusNew England Journal of Medicine, 1984
- Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet ActivationNew England Journal of Medicine, 1984
- Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.Circulation, 1983